Azienda Ospedaliera Per L'Emergenza Cannizzaro
- Address
- Via Messina 829, 95126 Catania, Italy
Neoplasms and Gynecologic Oncology
At Azienda Ospedaliera Per L'Emergenza Cannizzaro in Catania, clinical research in neoplasms focuses on cancers such as advanced epithelial ovarian cancer and advanced or recurrent endometrial cancer. These studies are designed to evaluate new treatment approaches and compare how well they control disease and extend survival.
- Advanced epithelial ovarian cancer
- Advanced or recurrent endometrial cancer
- Participants with advanced or recurrent endometrial carcinoma
- Testing combination therapies and maintenance strategies for better cancer control
Much of this work centers on improving outcomes for women with difficult-to-treat gynecologic cancers, including assessing whether newer targeted and immunotherapy-based options may offer more effective disease management.
Cardiovascular Diseases
Research in cardiovascular diseases at this site includes studies in acute myocardial infarction, with a focus on finding better ways to support recovery after a heart attack. The trials are intended to test whether a new therapy can improve heart-related outcomes and safety in people who have recently experienced this event.
- Acute myocardial infarction
- Evaluating a potential new treatment after heart attack
- Assessing safety, tolerability, and effectiveness in cardiac recovery
This line of research reflects the hospital’s interest in urgent cardiovascular care and in identifying treatments that may reduce complications after myocardial injury.
Digestive System Diseases
The site also conducts trials in digestive system diseases, especially Crohn's disease. These studies aim to determine whether a maintenance treatment can help sustain response, while also examining longer-term safety and symptom control in people with moderate to severe disease.
- Crohn's disease
- Testing maintenance treatment effectiveness
- Long-term evaluation of safety and disease control
For patients living with chronic intestinal inflammation, this research is aimed at improving durability of treatment benefit and supporting better day-to-day disease management.
Oncology and Prostate Cancer Research
Additional cancer studies at Azienda Ospedaliera Per L'Emergenza Cannizzaro include metastatic castration-resistant prostate cancer. The research is focused on comparing treatment effectiveness and survival outcomes, with the goal of identifying better options for advanced prostate cancer.
- Metastatic castration-resistant prostate cancer
- Comparing overall survival and progression control
- Evaluating new combination therapy approaches
These trials contribute to a broader oncology program that explores whether innovative regimens can offer more meaningful benefit for men with advanced, treatment-resistant disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 90 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 84 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1AstraZeneca AB6active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC9trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Per L'Emergenza Cannizzaro
lock Showing 1 of 56 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 90 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 18 | Unknown | 2018-12-18 | 2026-05-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.